Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASN 007 (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Asana BioSciences
  • Most Recent Events

    • 06 Dec 2019 Status changed from recruiting to active, no longer recruiting.
    • 30 Oct 2019 Results as of 25 Oct 19 (n=42) were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
    • 24 Oct 2019 According to an Asana Biosciences media release, data from this study will be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top